NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

3 Months Ended

Dec. 31, 2022

5. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of December 31,		As of September 30,
	2022		2022
	Unaudited		Audited
Accrued compensation and benefits	$	171,572	$	768,324
Accrued consulting settlement		225,000		150,000
Accrued professional fees		241,808		191,516
Accrued research and development		20,684		512,570
Accrued franchise tax		217,440		36,542
Accrued restructuring		316,032		—
Other accrued expenses		35,120		3,708
Total	$	1,227,656	$	1,662,660